Daratumumab/hyaluronidase(Hangzhou Jiuyuan Gene Biomedical Co Ltd)

N/A

Report date: 2025/11/05 11:09:12

Base Information

Drug NameDaratumumab/hyaluronidase(Hangzhou Jiuyuan Gene Biomedical Co Ltd)

Drug Alias NameDaratumumab(+hyaluronidase)biosimilar(Hangzhou Jiuyuan Gene Biomedical Co Ltd)达雷妥尤单抗（+透明质酸酶）生物类似药（杭州九源基因生物医药股份有限公司）Daratumumab biosimilar+hyaluronidase达雷妥尤单抗生物类似药（杭州九源基因生物医药股份有限公司）+透明质酸酶Daratumumab biosimilar(Hangzhou Jiuyuan Gene Biomedical Co Ltd)+hyaluronidase +[8]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionHyaluronic acid modulatorsAnti-CD38

TargetsHyaluronic acidLymphocyte differentiation antigen CD38

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering)

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A